non muscle invasive
Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
6
Diagnostic accuracy of MRI in differentiating non-muscle invasive from muscle invasive bladder carcinoma taking histopathological staging as a standard
6
Impact of oral hypoglycemic agents on mortality among diabetic patients with non muscle invasive bladder cancer: A population based analysis
21
Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ
10
Molecular Assessment of Non Muscle Invasive and Muscle Invasive Bladder Tumors: Mapping of Putative Urothelial Stem Cells and Toll Like Receptors (TLR) Signaling
13
Risk factor assessment in high-risk, bacillus Calmette–Guérin-treated, non-muscle-invasive bladder cancer
8
Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer
10
Genomic characterization of high-risk non-muscle invasive bladder cancer
9
Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non muscle invasive bladder cancer: Patients’ and urologic oncologists’ perspectives
18
The management of BCG failure in non muscle invasive bladder cancer: an update
7
Original Article TROP2 is associated with the recurrence of patients with non-muscle invasive bladder cancer
8
Canadian guidelines for treatment of non muscle invasive bladder cancer: a focus on intravesical therapy
6
Original Article MiR-20a in cell-free urine as a potential diagnostic biomarker for non-muscle invasive bladder cancer: a Chinese population-based study
8
Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer
6
Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma
8
The application of adjuvant autologous antravesical macrophage cell therapy vs BCG in non muscle invasive bladder cancer: a multicenter, randomized trial
6
Prognostic Value of Sex Hormone Receptor Expression in Non Muscle Invasive Bladder Cancer
8
Clinical rationale and safety of restaging transurethral resection in indication stratified patients with high risk non muscle invasive bladder cancer
6
Role of first check cystoscopy in non-muscle invasive bladder carcinoma: A prospective and historical cohort study
123
Prognostic Factors for Recurrence and Progression in Korean Non Muscle Invasive Bladder Cancer Patients: A Retrospective, Multi Institutional Study
10